Lachlan Brown
Stock Analyst at William Blair
(1.35)
# 3,462
Out of 4,905 analysts
10
Total ratings
50%
Success rate
-1.92%
Average return
Main Sectors:
Stocks Rated by Lachlan Brown
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MANH Manhattan Associates | Downgrades: Neutral | $270 → $200 | $202.05 | -1.01% | 2 | Jun 10, 2025 | |
| HROW Harrow | Initiates: Outperform | n/a | $35.89 | - | 1 | Jun 10, 2025 | |
| KLRS Kalaris Therapeutics | Initiates: Outperform | n/a | $2.39 | - | 1 | Apr 8, 2025 | |
| OCUL Ocular Therapeutix | Initiates: Outperform | n/a | $11.33 | - | 1 | Apr 8, 2025 | |
| SNPS Synopsys | Initiates: Buy | $600 | $584.76 | +2.61% | 1 | Jan 13, 2025 | |
| CDNS Cadence Design Systems | Initiates: Buy | $350 | $315.57 | +10.91% | 1 | Jan 13, 2025 | |
| APLS Apellis Pharmaceuticals | Initiates: Outperform | n/a | $19.47 | - | 1 | Oct 16, 2024 | |
| DSGX The Descartes Systems Group | Initiates: Neutral | $90 | $105.08 | -14.35% | 1 | May 14, 2024 | |
| SPSC SPS Commerce | Initiates: Buy | $220 | $138.98 | +58.30% | 1 | May 14, 2024 |
Manhattan Associates
Jun 10, 2025
Downgrades: Neutral
Price Target: $270 → $200
Current: $202.05
Upside: -1.01%
Harrow
Jun 10, 2025
Initiates: Outperform
Price Target: n/a
Current: $35.89
Upside: -
Kalaris Therapeutics
Apr 8, 2025
Initiates: Outperform
Price Target: n/a
Current: $2.39
Upside: -
Ocular Therapeutix
Apr 8, 2025
Initiates: Outperform
Price Target: n/a
Current: $11.33
Upside: -
Synopsys
Jan 13, 2025
Initiates: Buy
Price Target: $600
Current: $584.76
Upside: +2.61%
Cadence Design Systems
Jan 13, 2025
Initiates: Buy
Price Target: $350
Current: $315.57
Upside: +10.91%
Apellis Pharmaceuticals
Oct 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $19.47
Upside: -
The Descartes Systems Group
May 14, 2024
Initiates: Neutral
Price Target: $90
Current: $105.08
Upside: -14.35%
SPS Commerce
May 14, 2024
Initiates: Buy
Price Target: $220
Current: $138.98
Upside: +58.30%